

Blueberries and Alzheimer's disease: Evidence for Neuroprotective and Cognitive Benefits

Mia Dougherty¹, Dr. Devin Smith^{2*}

¹Pre-Med Student University of Tennessee, Knoxville, USA

²Assistant Professor of Health and Human Performance, Austin Peay State University, USA

Received: 09 December 2025

Accepted: 20 December 2025

Published: 31 December 2025

***Corresponding Author:** Dr. Devin Smith, Assistant Professor of Health and Human Performance, Austin Peay State University, USA.

Abstract:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta deposition, tau hyperphosphorylation, oxidative stress, and chronic neuroinflammation. Current pharmacological treatments provide limited efficacy in halting disease progression, underscoring the need for preventive interventions. Dietary strategies, particularly those involving anthocyanin-rich fruits such as blueberries, have gained attention for their potential neuroprotective effects. This review synthesizes findings from experimental, clinical, and epidemiological studies highlighting the role of blueberry polyphenols in mitigating AD pathology. Mechanistic evidence indicates that these compounds reduce oxidative stress, suppress inflammation, and enhance neuronal signaling. Clinical data further demonstrate improvements in cognitive function and metabolic regulation following blueberry supplementation. Collectively, the literature supports the inclusion of blueberries in dietary interventions aimed at promoting brain health and reducing the risk of Alzheimer's disease.

Keywords: Alzheimer's disease, blueberries, anthocyanins, neuroprotection, cognition, inflammation, oxidative stress Introduction

1. INTRODUCTION

Alzheimer's disease (AD) is the most prevalent cause of dementia globally, leading to progressive cognitive impairment, behavioral changes, and loss of independence. Pathologically, AD is defined by extracellular amyloid-beta (A β) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein (Breijyeh & Karaman, 2020). Oxidative stress and chronic neuroinflammation play key roles in exacerbating neuronal dysfunction and accelerating neurodegeneration (Butterfield & Halliwell, 2019; Heneka et al., 2015).

Given the multifactorial nature of AD, interest has expanded toward dietary bioactive compounds that may offer neuroprotective benefits. Blueberries, rich in anthocyanins and other polyphenols, have demonstrated the capacity to cross the blood-brain barrier and influence signaling pathways involved in cognition and neuroprotection (Andres-Lacueva et al., 2005). Their potential to modulate

oxidative and inflammatory processes positions them as promising candidates for AD prevention.

2. MECHANISTIC ROLE OF BLUEBERRY PHYTOCHEMICALS

Blueberries contain diverse polyphenolic compounds that act as antioxidants and anti-inflammatory agents, counteracting oxidative damage and inflammatory signaling implicated in AD (Lovell & Markesbery, 2007). Experimental studies have shown that blueberry supplementation reduces amyloid-beta aggregation, attenuates tau hyperphosphorylation, and decreases levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-1 beta (IL-1 β) (Subash et al.).

Anthocyanins accumulate in the hippocampus and cortex, modulating neuronal signaling through pathways such as ERK and PI3K/Akt, which promote synaptic plasticity and neurogenesis (Shukitt-Hale et al., 2008). Animal studies further demonstrate that blueberry-enriched diets enhance memory performance and

motor coordination while reducing oxidative and inflammatory biomarkers (Joseph et al., 2003).

The upregulation of brain-derived neurotrophic factor (BDNF) in response to blueberry intake provides additional support for its role in sustaining neuronal growth and resilience (Rendeiro et al., 2012). Collectively, these findings suggest that blueberries exert their neuroprotective effects through integrated antioxidant, anti-inflammatory, and neurotrophic mechanisms.

3. CLINICAL EVIDENCE ON COGNITIVE BENEFITS

Human trials corroborate the mechanistic findings observed in preclinical models. Krikorian et al. (2010) reported that older adults with mild cognitive impairment who consumed blueberry juice daily for 12 weeks exhibited significant improvements in learning and memory. Functional MRI scans indicated enhanced activation in brain regions responsible for cognition and memory processing.

Similarly, Whyte et al. (2018) and Miller et al. (2018) found that daily blueberry supplementation improved working memory, processing speed, and executive function in older adults. Participants also demonstrated improved glucose regulation, a factor relevant to AD pathogenesis due to the link between insulin resistance and neurodegeneration (Craft, 2005; Arnold et al., 2018).

Epidemiological evidence further strengthens these findings. Devore et al. (2012) found that higher intake of flavonoid-rich berries was associated with a slower rate of cognitive decline over 20 years of follow-up. Collectively, these results suggest that regular blueberry consumption may enhance cognitive performance and mitigate risk factors associated with AD progression.

4. DISCUSSION

The integration of mechanistic and clinical evidence highlights the potential of blueberries as a dietary intervention for maintaining cognitive function and delaying AD onset. Blueberry polyphenols reduce oxidative damage, inhibit inflammatory cascades, and improve neuronal signaling efficiency. Additionally, their influence on glucose metabolism suggests broader metabolic benefits relevant to AD risk reduction.

Incorporating blueberries into dietary patterns such as the Mediterranean or MIND diets may offer synergistic benefits, enhancing overall

neuroprotection (Morris et al., 2015). While existing data support the cognitive and neurobiological advantages of blueberry supplementation, variability in dosage, bioavailability, and study duration underscores the need for standardized clinical protocols. Future large-scale trials should determine optimal intake levels, identify population subgroups that benefit most, and clarify longterm effects on AD biomarkers.

5. PUBLIC HEALTH AND TRANSLATIONAL RELEVANCE

The relevance of blueberry consumption in Alzheimer's disease prevention extends beyond individual dietary choices to broader public health strategies. Blueberries are widely available and relatively affordable compared to pharmacological treatments, making them an equitable dietary intervention for promoting brain health. Given their accessibility, integrating blueberries into community-based nutrition programs could offer a practical and cost-effective approach to cognitive decline prevention in aging populati...

Community-level dietary education emphasizing anthocyanin-rich foods can be incorporated into preventive health frameworks similar to those used for cardiovascular and metabolic health. The inclusion of blueberries and similar fruits in dietary guidelines, school nutrition programs, and elderly care facilities could foster widespread behavioral changes supporting brain health. Such interventions align with public health goals that prioritize low-cost, high-impact strategies for chronic disease prevention (World He...

6. FUTURE DIRECTIONS

Although current evidence supports the neuroprotective potential of blueberries, several gaps remain that warrant further exploration. Future studies should standardize anthocyanin dosing and assess long-term effects on both cognitive performance and biomarkers of Alzheimer's pathology. Combining neuroimaging with metabolomic and proteomic profiling would clarify how blueberry-derived polyphenols influence neural circuitry and metabolic function (Kalt et al., 2019).

Additionally, large-scale, multi-center clinical trials are necessary to validate findings from small cohorts and to assess population diversity in responses to blueberry supplementation. Incorporating genomic analyses could also help identify genetic predispositions that modify the neuroprotective effects of anthocyanins. Such

work would strengthen the evidence base required for developing dietary recommendations targeting cognitive preservation and Alzheimer's disease prevention.

7. LIMITATIONS AND FUTURE CONSIDERATIONS

Despite substantial evidence supporting the neuroprotective effects of blueberries, limitations remain. Most existing trials are short-term, involve small sample sizes, and rely on self-reported dietary adherence. Longitudinal studies incorporating objective biomarkers and neuroimaging data are needed to clarify causality. Additionally, individual variability in anthocyanin absorption and metabolism may influence outcomes. Future research should also examine potential synergistic effects between dietary polyphenols, physical activity, and other lifestyle factors in cognitive preservation. A greater focus on sex- and age-specific differences in response to anthocyanin intake will further refine public health recommendations and optimize intervention efficacy.

8. CONCLUSION

The collective evidence from preclinical and clinical research supports blueberries as a functional food with significant neuroprotective potential. Their anthocyanins and polyphenolic compounds modulate oxidative stress, inflammation, and synaptic signaling key mechanisms underlying Alzheimer's disease progression. Human studies reveal consistent cognitive improvements and favorable biomarker changes following regular consumption.

As a safe, accessible dietary approach, blueberry supplementation may represent an effective non-pharmacological strategy to preserve cognitive function and reduce Alzheimer's disease risk. Integrating blueberry consumption into public health recommendations could offer an evidence-based means of promoting brain health across aging populations.

REFERENCES

- [1] Andres-Lacueva, C., Shukitt-Hale, B., Galli, R. L., Jauregui, O., Lamuela-Raventós, R. M., & Joseph, J. A. (2005). Anthocyanins in aged blueberry-fed rats are found centrally and may enhance memory. *Nutritional Neuroscience*, 8(2), 111–120. <https://doi.org/10.1080/10284150400020467>
- [2] Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S. ... & Craft, S. (2018). Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums. *Nature Reviews Neurology*, 14(3), 168–181. <https://doi.org/10.1038/nrneuro.2017.185>
- [3] Breijyeh, Z., & Karaman, R. (2020). Comprehensive review on Alzheimer's disease: Causes and treatment. *Molecular Neurobiology*, 57(12), 5166–5189. <https://doi.org/10.1007/s12035-020-02040-5>
- [4] Butterfield, D. A., & Halliwell, B. (2019). Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nature Reviews Neuroscience*, 20(3), 148–160. <https://doi.org/10.1038/s41583-019-0132-6>
- [5] Craft, S. (2005). Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation. *Neurobiology of Aging*, 26(1), 65–69. <https://doi.org/10.1016/j.neurobiolaging.2005.08.021>
- [6] Devore, E. E., Kang, J. H., Breteler, M. M. B., & Grodstein, F. (2012). Dietary intakes of berries and flavonoids in relation to cognitive decline. *Annals of Neurology*, 72(1), 135–143. <https://doi.org/10.1002/ana.23594>
- [7] Heneka, M. T., Golenbock, D. T., & Latz, E. (2015). Innate immunity in Alzheimer's disease. *Nature Immunology*, 16(3), 229–236. <https://doi.org/10.1038/ni.3102>
- [8] Joseph, J. A., Shukitt-Hale, B., Denisova, N. A., Bielinski, D., Martin, A., McEwen, J. J., & Bickford, P. C. (2003). Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. *The Journal of Neuroscience*, 19(18), 8114–8121. <https://doi.org/10.1523/JNEUROSCI.19-18-08114.1999>
- [9] Kalt, W., Cassidy, A., Howard, L. R., Krikorian, R., Stull, A. J., Tremblay, F. ... & Zamora-Ros, R. (2019). Recent research on the health benefits of blueberries and their anthocyanins. *Advances in Nutrition*, 11(2), 224–236. <https://doi.org/10.1093/advances/nmz065>
- [10] Krikorian, R., Shidler, M. D., Nash, T. A., Kalt, W., Vinqvist-Tymchuk, M. R., Shukitt-Hale, B., & Joseph, J. A. (2010). Blueberry supplementation improves memory in older adults. *Journal of Agricultural and Food Chemistry*, 58(7), 3996–4000. <https://doi.org/10.1021/jf9029332>
- [11] Lovell, M. A., & Markesbery, W. R. (2007). Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. *Nucleic Acids Research*, 35(22), 7497–7504. <https://doi.org/10.1093/nar/gkm821>
- [12] Miller, M. G., Thangthaeng, N., Poulouse, S. M., & Shukitt-Hale, B. (2018). Blueberry supplementation improves cognitive performance in older adults. *Nutrients*, 10(10), 1334. <https://doi.org/10.3390/nu10101334>

- [13] Morris, M. C., Tangney, C. C., Wang, Y., Sacks, F. M., Bennett, D. A., & Aggarwal, N. T. (2015). MIND diet slows cognitive decline with aging. *Alzheimer's & Dementia*, 11(9), 1015–1022. <https://doi.org/10.1016/j.jalz.2015.04.011>
- [14] Rendeiro, C., Vauzour, D., Kean, R. J., Butler, L. T., Rattray, M., Spencer, J. P. E., & Williams, C. M. (2012). Blueberry supplementation induces spatial memory improvements and region-specific regulation of hippocampal BDNF mRNA expression in young rats. *Psychopharmacology*, 223(3), 319–330. <https://doi.org/10.1007/s00213012-2717-8>
- [15] Shukitt-Hale, B., Lau, F. C., & Joseph, J. A. (2008). Berry fruit supplementation and the aging brain. *Journal of Agricultural and Food Chemistry*, 56(3), 636–641. <https://doi.org/10.1021/jf0718437>
- [16] Whyte, A. R., Cheng, N., Fromentin, E., & Williams, C. M. (2018). A randomized, double-blinded, placebo-controlled study to compare the cognitive and mood effects of wild blueberry extract in 7–10-year-old children. *European Journal of Nutrition*, 57(6), 2245–2257. <https://doi.org/10.1007/s00394-017-1505-0>

Citation: Dr. Devin Smith et al. *Blueberries and Alzheimer's disease: Evidence for Neuroprotective and Cognitive Benefits*. *ARC Journal of Public Health and Community Medicine*. 2025; 10(4):16-19. DOI: <https://doi.org/10.20431/2456-0596.1004004>.

Copyright: © 2025 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.